Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DV Biomed CoROCO:6539 66 EV-to-EBITDA is 5.33 as of Sep. 09, 2026, which is 37% below its 10-year median of 8.40. GuruFocus rates ROCO:6539 with a GF Score™ of 66/100 and a GF Value™ of NT$74.31 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 726 Drug Manufacturers companies, DV Biomed Co ranks better than 84.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DV Biomed Co's enterprise value is NT$677.6 Mil.
DV Biomed Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$127.2 Mil. Therefore, DV Biomed Co's EV-to-EBITDA for today is 5.33.
The historical rank and industry rank for DV Biomed Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6539'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.19 Med: 8.4 Max: 25.02
Current: 5.33
During the past 13 years, the highest EV-to-EBITDA of DV Biomed Co was 25.02. The lowest was 4.19. And the median was 8.40.
ROCO:6539's EV-to-EBITDA is ranked better than 84.3% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.4
vs ROCO:6539: 5.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DV Biomed Co's PE Ratio (TTM) for today is calculated as:
DV Biomed Co's share price for today is NT$41.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DV Biomed Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$3.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DV Biomed Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DV Biomed Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DV Biomed Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DV Biomed Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DV Biomed Co's EV-to-EBITDA falls into.
DV Biomed Co's current Enterprise Value is NT$677.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DV Biomed Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$127.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DV Biomed Co (ROCO:6539) has a EV-to-EBITDA of 5.33 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DV Biomed Co. This is 37% below median its historical median of 8.40. Over the past decade, DV Biomed Co's EV-to-EBITDA has ranged from 4.19 to 25.02. According to the industry distribution chart, DV Biomed Co ranks #114 out of 726 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is DV Biomed Co's EV-to-EBITDA too high?
DV Biomed Co's current EV-to-EBITDA of 5.33 is 37% below median its 10-year median of 8.40. Over the past 10 years, this metric has ranged from a low of 4.19 to a high of 25.02. The Drug Manufacturers industry median EV-to-EBITDA is 13.40. DV Biomed Co's value of 5.33 is 60.2% below this industry median. Based on the distribution chart, DV Biomed Co ranks #114 out of 726 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DV Biomed Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DV Biomed Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DV Biomed Co ranks #114 out of 726 companies for EV-to-EBITDA. This places DV Biomed Co in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.40. DV Biomed Co's value of 5.33 is 60.2% below this benchmark. Historically, DV Biomed Co's own EV-to-EBITDA has ranged from 4.19 to 25.02 over the past decade. While the company's 10-year median is 8.40 vs. the industry median of 13.40, DV Biomed Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.40, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DV Biomed Co's current EV-to-EBITDA of 5.33 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DV Biomed Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DV Biomed Co's current EV-to-EBITDA is 5.33, which is 37% below median its own 10-year median of 8.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DV Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, DV Biomed Co (ROCO:6539) is currently considered Possible Value Trap. The stock's GF Value™ is NT$74.31, compared to a current price of NT$41.05 — trading 44.8% below its estimated fair value. The current EV-to-EBITDA is 5.33, which is 37% below median its 10-year median of 8.40 and 60.2% below the Drug Manufacturers industry median of 13.40. DV Biomed Co's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DV Biomed Co (ROCO:6539), the current EV-to-EBITDA is 5.33 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DV Biomed Co (ROCO:6539) Overvalued in 2026?
Based on GuruFocus' analysis, DV Biomed Co stock appears to be undervalued.
The current stock price of NT$41.05 is trading 44.8% below its estimated GF Value™ of NT$74.31.
GuruFocus considers DV Biomed Co to be Possible Value Trap.
Key valuation signals for ROCO:6539:
EV-to-EBITDA: 5.33 (37% below median its 10-year median of 8.40)
GF Value™: NT$74.31 vs. price of NT$41.05 (44.8% below fair value)
Industry Position: 60.2% below the Drug Manufacturers median (#114 of 726)
No single metric tells the full story. See the ROCO:6539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DV Biomed Co Ltd provides medical supplies, skincare, and healthcare products. Its products include Perfectin and L'AMOUR Isis. The company also provides medical materials and needles (medicine), and healthcare products.
66GF Score
Get the complete analysis for ROCO:6539
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6539 has been successfully added to your 
